FDA Alerts
FDA Expands Zytiga’s use for Late-Stage Prostate Cancer
The US Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.
FDA approves Zytiga for late-stage prostate cancer
The U.S. Food and Drug Administration (FDA) today approved Zytiga ( abiraterone acetate) in combination with prednisone (a steroid) to treat patients with late-stage (metastatic) castration-resistant prostate cancer who have received prior docetaxel (chemotherapy).